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Background: In ulcerative colitis (UC), inflammatory damage is associated with increased production of
pro-inflammatory cytokines and nitric oxide through the inducible nitric oxide synthase (iNOS) pathway.
In an animal model of acute experimental colitis we have previously shown amelioration of inflammation
with the highly selective iNOS inhibitor 1400 W. The aim of the present study was to investigate the
effects of selective iNOS inhibition on the production of pro-inflammatory cytokines by the colon mucosa
in UC. Methods: Inflamed and uninflamed mucosa from patients with severe UC were incubated with a
highly selective iNOS inhibitor N-[3-(aminomethyl)benzyl]acetamidine (1400 W), with a relatively
selective cNOS inhibitor N(G)-nitro-L-arginine-methyl-esther (L-NAME), or with an NO-donor,
S-nitroso-acetylpenicillamine (SNAP). Cytokine concentrations in the incubation medium were
quantitated with ELISA. Results: Compared to uninflamed mucosa there was an increase in iNOS
protein and nitrotyrosine levels in inflamed mucosal samples. Immunolocalization of iNOS and nitro-
tyrosine showed their expression in inflammatory cells in the lamina propria. Expression of iNOS was
also found in the epithelial brush border. Selective inhibition of iNOS suppressed the release of tumour
necrosis factor alpha (TNF-, by 66%) and interleukin-6 (IL-6, by 27%). The NO-donor, SNAP,
augmented the secretion of TNF-, IL-6 and IL-1- (by 62%, 52% and 175%, respectively) and decreased
the release of IL-1 receptor antagonist (IL-1Ra, by 34%) by the inflamed mucosa. Moreover, in
uninflamed samples, 1400 W suppressed the production of TNF- (by 69%) and incubation with SNAP
decreased IL-6 concentrations by 48%. The cNOS over iNOS selective inhibitor L-NAME had no
significant effects on the accumulation of cytokines. Conclusion: Selective inhibition of iNOS suppresses
mucosal TNF- and IL-6 release in active UC, whereas NO seems to exacerbate the inflammatory
response. These results suggest that selective iNOS inhibition may have therapeutic promise in the
treatment of UC.
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The colon mucosa in ulcerative colitis (UC) producesincreased amounts of pro-inflammatory cytokinessuch as interleukin-1 beta (IL-1), tumour necrosis
factor-alpha (TNF-) and interleukin-6 (IL-6) (1–3). The
main cellular sources of these cytokines are activated mono-
cytes and macrophages (4–6). The increased production of
these pro-inflammatory cytokines correlates with disease
activity in inflammatory bowel diseases (1, 7) and their syn-
thesis is implicated in the pathogenesis of the disease (6). In
addition, inflamed tissue produces cytokine antagonists to
endogenously control their actions and to limit inflammation
(8). One of these cytokine antagonists is the IL-1 receptor
antagonist (IL-1Ra), which binds to the IL-1 receptor and
thereby suppresses IL-1 signalling (9).
Active inflammation in UC is also associated with
increased expression of the inducible, calcium-independent
nitric oxide (NO) synthase (iNOS, NOS-2) (10). iNOS is
capable of producing high amounts of NO (11) and is
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regarded as the principal source of NO in gut inflammation
(12, 13). The expression of iNOS is induced by certain pro-
inflammatory stimuli such as IL-1, TNF- and bacterial
products (11, 12). Increased iNOS activity and NO production
contribute to inflammation and oxidative stress through the
reaction of NO with superoxide leading to the formation of a
highly cytotoxic oxidant, the peroxynitrite anion (14, 15).
Small amounts of NO are produced for physiological
purposes by the constitutively expressed, calcium-dependent,
enzymes: endothelial (eNOS, NOS-3) and neuronal NOS
(nNOS, NOS-1) (11). NO contributes to several central func-
tions in immune regulation (16), and an NO-releasing amino-
salicylate-derivative has been shown to exert beneficial
effects on colon inflammation in experimental models
(17, 18).
Recently, we showed that the inflammatory process
associated with induction of iNOS in an acute model of rat
colitis (19) was suppressed by a highly selective inhibitor of
iNOS, 1400 W (20, 21). Our finding agrees with other reports
on the advantageous effects of NOS inhibitors in the treat-
ment of experimentally induced colitis (22–27). In the present
study we provide further insight into these mechanisms and
investigate the effects of a selective iNOS inhibitor 1400 W
on the release of pro-inflammatory cytokines from colon
mucosa of patients with severe UC.
Materials and Methods
Patients
The patient characteristics are given in Table I. All patients
were on oral steroids and 5-aminosalicylic acid (5-ASA).
They underwent elective proctocolectomy because of severe
disease, failure of conventional treatment, or because of
adverse drug effects. As an indicator of the ongoing
inflammation, the patients’ mean blood leucocyte count at
time of operation was 10.2 1.1 109 l1. Their disease was
histopathologically verified as UC (Helsinki University
Central Hospital Laboratory Diagnostics, Department of
Pathology, Helsinki, Finland) from comparative samples as
used in the present study. Two of seven patients had been
diagnosed with pancolitis; the other patients had diagnosed
inflammation of descending colon only. At time of collecting
the mucosal samples, the descending colon was most inflamed
by eye in all cases, whereas macroscopically uninflamed
mucosa was present in the ascending and transverse colon.
Incubation of colon mucosal samples
Immediately after removal, the colon was longitudinally
opened and 4 cm2 samples of mucosa were cut from inflamed
and uninflamed regions. The samples were placed in separate
containers containing 500 mL of ice-cold phosphate buffered
saline (PBS) for transport. Thereafter (approximately after
15 min) the tissues were washed in fresh ice-cold PBS.
Mucosal samples were cut with a curette (4 mL in diameter).
Each sample was placed in 800 L PBS in a cell culture plate.
After 30 min pre-incubation, the PBS was replaced with
400 L of culture medium (RPMI 1640 containing antibio-
tics: penicillin 100 U mL1, streptomycin 0.1 mg mL1, and
amphotericin B 250 ng mL1) supplemented with the test
compounds. Both uninflamed and inflamed mucosal samples
were divided into four groups, one group with vehicle (culture
medium only), one with L-NAME (1 mM), one with 1400 W
(1 mM), and one group with SNAP (500 M). The concen-
trations were chosen for sufficient mucosal tissue sample
(50–60 mg) penetration by the drugs from the relatively small
volume (400 L) of incubation medium. The culture plates
were kept in a humidified atmosphere consisting of 95% air
and 5% CO2 at 37°C for 5 h. After incubation, the medium
and mucosal samples were collected and immediately frozen
in liquid nitrogen and stored at 70°C until analysed.
Enzyme-linked immunosorbent assay (ELISA)
Cytokines IL-1, IL-6 and TNF- were analysed by ELISA
using reagents supplied by Central Laboratory of The
Netherlands Red Cross (CLB), The Netherlands (PeliPair
reagent sets). IL-1Ra was analysed by ELISA using reagents
from R&D Systems, USA (Quantikine).
Immunohistochemistry
Mucosal samples were embedded in Tissue Tek O. C. T.
Compound (Sakura Finetek Inc., Zoeterwoude, The Nether-
lands). Cryostat sections were air dried and fixed in ice-cold
methanol. Endogenous peroxidase activity was quenched
with subsequent incubation in PBS containing 0.3% hydrogen
Table I. Patient characteristics
Drug treatment at time of operation
# Male (M)/Female (F) Age Years from diagnosis Peroral steroid, mg/day 5-ASA* mg/day Azathioprine mg/day
1 M 57 2 Prednisone, 5 prednisolone, 25 rectally 2400 —
2 F 31 8 Prednisone, 10 3200 —
3 F 27 3.5 Methylprednisolone, 40 3200 —
4 F 35 4 Methylprednisolone, 24 2400 —
5 M 32 1.5 Prednisone, 20 3200 —
6 M 44 5.5 Prednisolone, 15 2400 —
7 M 46 2.5 Prednisone, 30 3200 75
*5-ASA = 5-aminosalicylic acid.
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peroxide. The sections were then washed three times with ice-
cold PBS, incubated in normal blocking serum, washed and
incubated overnight with the primary antibody. Thereafter the
sections were processed according to the avidin-biotin-
peroxidase procedure (Vectastain ABC Elite-kit, Vector
Laboratories, Burlingame, Calif., USA). Monoclonal anti-
iNOS at a dilution of 1:2000 (Transduction Laboratories,
Franklin Lakes, N.J., USA) and polyclonal anti-nitrotyrosine
at a dilution of 1:500 (Upstate Biotechnology, Lake Placid,
NY, USA) were used as primary antibodies. Respective non-
immune serum was used instead of primary or secondary
antibody as negative controls. Rabbit/mouse IgG of the same
sub-type as the primary antibody but with an irrelevant
specificity was used as an additional negative control. The
sections were counterstained with haematoxylin.
Western blot
Western blots for iNOS and nitrotyrosine were carried out
using previously described protocols (21). The nitrotyrosine
antibody was from Upstate Biotechnology, the monoclonal
eNOS and nNOS antibodies were from Transduction Labora-
tories, and the monoclonal iNOS antibody was from Santa
Cruz Biotechnology (Santa Cruz, Calif., USA). Densitometric
analysis was carried out using specific computer programs
GeneSnap Version 2.60.0.14 and GeneTools Version 2.10.03
(Synoptics, Cambridge, UK).
Materials
L-NAME and SNAP were purchased from Sigma Chemical
Co. (St. Louis, Mo., USA). 1400 W was kindly provided by
Dr. Richard G. Knowles, Glaxo SmithKline (Stevenage, UK).
RPMI-1640 and the antibiotics were purchased from Gibco
BRL (NY, USA). Culture plates were from Nunc (Copen-
hagen, Denmark) and curettes from Stiefel Laboratories Ltd.
(Sligo, Ireland).
Ethics
The study plan was approved by the Ethics Committee of
Helsinki University Central Hospital, Dept. of Surgery,
Helsinki, Finland.
Statistics
Statistical analyses for densitometric studies were carried
out using two-tailed paired t test, and for the drug treatment
studies using the analysis of variance (ANOVA); intergroup
comparisons were made using the Bonferroni’s post-test, P
values 0.05 were considered significant. All data are ex-
pressed as mean sx (standard error of the mean).
Results
The expression of iNOS was about 10-fold higher in the
inflamed samples of colon mucosa as compared to macro-
scopically healthy mucosa (Fig. 1). In contrast, no differences
in the expressions of the constitutive NOS isoforms, eNOS
and nNOS, were found between the inflamed and the
quiescent mucosa (Figs. 2 and 3). Nitrotyrosine was measured
as a marker of peroxynitrite production. Immunoblotting of
nitrotyrosine expression in the inflamed mucosa revealed
scantly, but non-significantly elevated levels of nitrotyrosine
in inflamed mucosa as compared to the uninflamed samples
(data not shown). Localization of iNOS and nitrotyrosine by
immunohistochemistry showed their predominant expression
in infiltrated inflammatory cells. iNOS was also localized to
the apical epithelial brush border in some areas (Fig. 4).
All mucosal samples produced detectable amounts of IL-6,
TNF- and IL-1 into the culture medium. Incubation of the
inflamed mucosa with the highly selective iNOS inhibitor
1400 W decreased the accumulation of IL-6 by 27% and
TNF- by 66% (Fig. 5), but had no effect on IL-1 or IL-1Ra
secretion as compared to untreated inflamed control samples
Fig. 1. (a) Expression of inducible nitric oxide synthase (iNOS) and
(b) densitometry of iNOS expression in macroscopically inflamed
and uninflamed, quiescent mucosal samples from the seven patients
with ulcerative colitis. In (b), data are expressed as mean  sx (SE),
**P 0.01 as compared to uninflamed mucosa.
Fig. 2. (a) Expression of endothelial nitric oxide synthase (eNOS)
and (b) densitometry of eNOS expression in macroscopically in-
flamed and uninflamed, quiescent mucosal samples from the seven
patients with ulcerative colitis. In (b), data are expressed as
mean sx (SE).
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(Fig. 6). The relatively cNOS over iNOS selective inhibitor
L-NAME had no significant effects on cytokine accumulation.
In contrast, treatment with NO-donor SNAP increased the
production TNF- (by 62%), IL-6 (by 52%) and IL-1 (by
175%). SNAP also inhibited the production of IL-1Ra by 34%
(Figs. 5 and 6) suggesting pro-inflammatory action of NO-
supplementation in inflamed colitic mucosa.
Incubation of macroscopically uninflamed, quiescent mu-
cosal samples with the selective iNOS inhibitor, 1400 W,
decreased TNF- concentrations by 69% (Fig. 7), but had no
effect on IL-6 (Fig. 7) or IL-1 (data not shown) concentra-
tions. Interestingly, treatment of uninflamed mucosa with the
NO-donor SNAP decreased IL-6 accumulation by 48%, but
had no effect on TNF- (Fig. 7) or IL-1 (data not shown).
Treatment with L-NAME showed no significant effect on
cytokine production by the uninflamed mucosa.
Fig. 4. Immunohistochemical localization of inducible nitric oxide synthase (iNOS) and nitrotyrosine in
inflamed colon mucosa. (a) iNOS positive inflammatory cells in lamina propria, (b) iNOS positive
staining in apical epithelial cell brush border, (c) nitrotyrosine positive staining in cells of lamina propria,
and (d) negative control section incubated with non-immune serum instead of primary antibody.
Fig. 3. (a) Expression of neuronal nitric oxide synthase (nNOS) and
(b) densitometry of nNOS expression in macroscopically inflamed
and uninflamed, quiescent mucosal samples from the seven patients
with ulcerative colitis. In (b), data are expressed as mean  sx (SE).
Fig. 5. The effects of L-NAME, 1400 W and SNAP on concen-
trations of (a) tumour necrosis factor-alpha (TNF-), and (b)
interleukin-6 (IL-6) in incubation medium of inflamed colon mucosa
from the seven patients with UC. Data are expressed as mean  sx
(SE), *P 0.05, ***P 0.001 as compared to untreated control.
Scand J Gastroenterol 2003 (2)































































Recently, we reported a beneficial effect of selective iNOS
inhibition in a rat model of acute colitis (21). In the present
study we investigated the effect of the highly selective iNOS
inhibitor, 1400 W, on the production of pro-inflammatory
cytokines TNF-, IL-6 and IL-1 in mucosal samples from
patients with UC. In the inflamed colon mucosa, 1400 W
suppressed the accumulation of TNF- and IL-6 in the
incubation medium, while SNAP, and NO donor, increased
their release. The iNOS selective inhibitor also decreased
TNF- release from uninflamed mucosa. SNAP aggravated
mucosal inflammation also by increasing IL-1 and suppres-
sing IL-1Ra production thus causing a disruption of the IL-1/
IL-1Ra balance in active disease. These results suggest that
selective iNOS inhibition may have anti-inflammatory effects
in UC.
Immunoblotting for iNOS, and marginally also for nitro-
tyrosine, showed their increase in the inflamed mucosa as
compared with samples from uninflamed areas. The expres-
sion of iNOS and presence of nitrotyrosine were found
predominantly in inflammatory cells of the lamina propria.
iNOS was also found in the brush border of the epithelial
cells. This pattern of iNOS and nitrotyrosine expression is
supported by previous findings in inflammatory bowel disease
(28, 29). Tyrosine nitration has been widely used as a marker
of peroxynitrite formation. Despite the fact that peroxynitrite-
independent mechanisms of tyrosine nitration exist (30), the
formation of nitrotyrosine reflects the overall amount of local
oxidative and nitrosative stress, and the production of
different nitrating species (31). It is feasible to assume that
an increased iNOS expression in the inflamed mucosa, as
found in the present study, is capable of high-output
generation of NO, which rapidly reacts with the superoxide
anion produced by inflammatory cells leading to the forma-
tion of peroxynitrite and nitrotyrosine. In inflammatory
conditions, iNOS may also produce superoxide and thus
contribute directly to oxidative stress (32).
Incubation of inflamed mucosa with 1400 W reduced the
release of IL-6 and TNF-, suggesting that in the colitic
mucosa of UC, iNOS activity stimulates and drives pro-
inflammatory cytokine release. SNAP, on the other hand,
increased the secretion of IL-1, IL-6, TNF-, whereas it
decreased IL-1Ra release by the inflamed mucosa. These
findings are in concert with the previously reported positive
feedback mechanism of nitric oxide on cytokine release (33)
and on TNF- production in activated human neutrophils and
mononuclear cells (34–36). In tissue devoid of macroscopic
inflammation, treatment with the NO-donor SNAP signi-
ficantly inhibited the accumulation of IL-6 showing the
opposing anti-inflammatory potential of NO. Thus, the detri-
mental effects of NO can be enhanced in active disease, while
in inactive disease NO may have anti-inflammatory activity.
Inflamed tissues produce IL-1Ra, a cytokine antagonist,
which acts as an endogenous suppressor of the pro-inflam-
matory responses of IL-1 (37). Imbalanced production of IL-1
and IL-1Ra in UC aggravates the inflammatory reaction (38).
In the inflamed colon mucosa, as seen in the present study,
exogenous NO increased the production of IL-1 and de-
creased IL-1Ra. In light of these results, NO may exacerbate
active mucosal inflammation by disrupting the IL1/IL1Ra
balance even further.
The mechanisms through which the high-output NO
generation by iNOS regulates cytokine release are not clear.
The mitogen activated protein kinase (MAPK) cascade can be
activated by peroxynitrite (39) and NO (40, 41) resulting in
enhanced activity of transcription factors such as NF-B and
activating protein-1 (AP-1) (42, 43). The activation of NF-B
is associated with increased production of IL-6 and TNF-
(44–46), and the AP-1 family of transcriptional activators
functions in cooperation with NF-B contributing to for
example increased transcription of TNF- (42). It was
Fig. 6. The effects of L-NAME, 1400 W and SNAP on concen-
trations of (a) interleukin-1 beta (IL-1) and (b) IL-1 receptor
antagonist (IL-1Ra) in incubation medium of inflamed colon mucosa
from the seven patients with UC. Data are expressed as mean  sx
(SE), *P 0.05, **P 0.01 as compared to untreated control.
Fig. 7. The effects of L-NAME, 1400 W and SNAP on concen-
trations of (a) tumour necrosis factor-alpha (TNF-) and (b)
interleukin-6 (IL-6) in incubation medium of macroscopically
uninflamed, quiescent colon mucosa from the seven patients with
UC. Data are expressed as mean sx (SE), *P 0.05, **P 0.01
as compared to untreated control.
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recently reported that NO may augment cytokine-induced
AP-1 activation also through cyclic-GMP-dependent protein
kinase (47), suggesting that NO may have both direct and
indirect actions on activation of pro-inflammatory cytokine
genes (48). Also a more direct action of NO and oxidative
stress has been reported on TNF-. They have been shown to
activate the TNF--converting enzyme, thus increasing
TNF- release (49, 50). These data are well in concert with
the present results, since selective inhibition of iNOS,
leading to decreased production of NO and peroxynitrite,
inhibited TNF- release from both inflamed and uninflamed
samples.
We have previously shown that selective inhibition of
iNOS with 1400 W decreases macroscopic mucosal lesions,
inflammatory edema, and granulocyte infiltration in experi-
mentally induced acute colitis in the rat (21). In that study, the
NOS-inhibitor L-NAME, the selectivity of which favors
cNOS over iNOS, produced no significant anti-inflammatory
effects. The results of the present study further suggest that
anti-inflammatory benefits are provided through selective
inhibition of iNOS rather than inhibition of the constitutive
NOS isoforms in colon inflammation. However, the detri-
mental role of iNOS in gut inflammation has been disputed
(51, 52). Data from experimental models suggest that induc-
tion of iNOS may also contribute to resolution of inflamma-
tion (52), and that a basal, physiological induction of iNOS in
the gut is required for prevention of bacterial overgrowth (53).
Even though iNOS seems to have protective effects in gut
mucosa (54), the pathological actions, e.g. oxidative and
nitrosative stress related NO-metabolism and persistent T-cell
activation in chronic inflammatory disease may overcome or
prevent these beneficial actions.
In conclusion, our results support the hypothesis that
selective inhibition of iNOS down-regulates mucosal in-
flammation by suppressing TNF- and IL-6 production in
UC-mucosa. These results warrant further investigation of
NO-related therapies, and suggest that selective inhibitors of
iNOS have therapeutic potential in the treatment of UC.
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